Clinical correlation of circulating heat shock protein 70 in acute leukemia

Abstract The heat shock protein 70 (HSP70) is one of the molecular chaperone family involved in the protection of cells upon exposure to various types of stresses. Plasma circulating HSP70 (cHSP70) is believed to play a role in the anti-tumor immune responses and its levels may reflect the levels of...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia research 2010-05, Vol.34 (5), p.605-609
Main Authors: Yeh, Chen-Hsiung, Tseng, Richard, Hannah, Alison, Estrov, Zeev, Estey, Elihu, Kantarjian, Hagop, Albitar, Maher
Format: Article
Language:English
Subjects:
Acute leukemia
Adolescent
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor - blood
Circulating heat shock protein
Female
Hematology, Oncology and Palliative Medicine
HSP70 Heat-Shock Proteins - blood
Humans
Immunoassay
Kaplan-Meier Estimate
Leukemia, Myeloid, Acute - blood
Leukemia, Myeloid, Acute - mortality
Luminescent Measurements
Male
Middle Aged
Precursor Cell Lymphoblastic Leukemia-Lymphoma - blood
Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality
Prognosis
Survival
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The heat shock protein 70 (HSP70) is one of the molecular chaperone family involved in the protection of cells upon exposure to various types of stresses. Plasma circulating HSP70 (cHSP70) is believed to play a role in the anti-tumor immune responses and its levels may reflect the levels of severity or the disease condition. Using electrochemiluminescence protein detection immunoassay, we measured the cHSP70 levels in the plasma of patients with acute myeloid leukemia (AML) ( n = 96), myelodysplastic syndrome (MDS) ( n = 28), and acute lymphoblastic leukemia (ALL) ( n = 40) and compared with those in normal individuals ( n = 99). cHSP70 levels were significantly higher in AML (median: 10.71 ng/mL, range: 1.93–79.0 ng/mL) and ALL (median: 27.59 ng/mL, range: 5.09–129.6 ng/mL) as compared to those in MDS (median: 4.54 ng/mL, range: 1.35–58.3 ng/mL) or healthy controls (median: 4.13 ng/mL, range: 1.75–13.6 ng/mL). Levels of cHSP70 showed significant positive correlation with lactate dehydrogenase (LDH) and white blood cells (WBC) in AML and ALL patients, which may reflect overall tumor load. Furthermore, patients with higher levels of cHSP70 had significantly shorter survival in AML ( P = 0.04) and ALL ( P = 0.05), suggesting that in these two acute diseases, cHSP70 is an indicator for poor prognosis. Our data support the potential of using free cHSP70 as a biomarker in leukemias and potentially other types of cancers.
ISSN:0145-2126
1873-5835
DOI:10.1016/j.leukres.2009.09.014